199331-40-3

Usage

InChI:InChI=1/C24H30Cl2O6/c1-4-31-21(30)24(32-20(29)19(25)26)10-8-16-15-6-5-13-11-14(27)7-9-22(13,2)18(15)17(28)12-23(16,24)3/h7,9,11,15-19,28H,4-6,8,10,12H2,1-3H3/t15-,16-,17-,18+,22-,23-,24?/m0/s1

Upstream product

• 64-67-5 diethyl sulfate 
• 199331-37-8 17α-dichloroacetoxy-11β-hydroxyandrosta-1,4-diene-3-one-17β-carboxylic acid 
• 75-03-6 ethyl iodide 
• 50-24-8 prednisolon 
• 50-23-7 HYDROCORTISONE 
• 750645-40-0 17α-dichloroacetoxy-11β-hydroxyandrost-4-en-3-one-17β-carboxylic acid 
• 3597-45-3 cortienic acid 
• 37927-29-0 (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0 0^2,7. 0^11,15]heptadeca-3,6-diene-14-carboxylic acid 
• 750645-48-8 ethyl 17α-dichloroacetoxy-11β-hydroxyandrost-4-en-3-one-17β-carboxylate 

Relevant academic research and scientific papers

POTENT SOFT ANTI-INFLAMMATORY CORTICOSTEROID COMPOUNDS AND USES THEROF

Potent soft corticosteroid pharmaceutical compositions comprising them and method for use as anti-inflammatory agents. Also, a method for softening fluticasone propionate and similar corticosteroids to arrive at potent but safer alternatives. The compound S-fluoromethyl 17α-dichloroacetoxy-6α,9α-difluoro-11β-hydroxy-16a- methyl-3-oxoandrosta-1,4-diene-17β-carbothioate, which is equally potent to but safer than fluticasone, is among those provided. Another compound of particular interest is 2-hydroxyethyl 17α-dichloroacetoxy-6α,9α-difluoro-11β-hydroxy-16β- methyl-3-oxoandrosta-1,4-diene-17β-carboxylate.

Etiprednol dicloacetate, a new soft glucocorticoid drug candidate. Development of chemistry

During development of chemistry of the soft drug candidate etiprednol dicloacetate (BNP-166) 1) optimization studies on the three-step chemical synthesis resulted in a process that could be scaled-up to the kg level, 2) the impurity profile was determined, 3) synthetic routes were developed for the preparation of the radiolabeled target compound, and 4) a series of hydroxylated metabolites was prepared.

ANDROSTENE DERIVATIVES

The invention provides new androstene derivatives having anti-inflammatory activity, pharmaceutical compositions containing them, and methods of administering them to warm-blooded animals in the treatment of inflammation. The active compounds are alkyl 17 alpha -dichloroacetoxy-11 beta -hydroxyandrosta-1,4-dien-3-one-17 beta -carboxylates and related androstenes.

Androstene derivatives

The invention provides new androstene derivatives having anti-inflammatory activity, pharmaceutical compositions containing them, and methods of administering them to warm-blooded animals in the treatment of inflammation. The active compounds are alkyl 17α-dichloroacetoxy-11β-hydroxyandrosta-1,4-dien-3-one-17β-carboxylates and related androstenes.